Rafferty Asset Management
ZNTL icon

Rafferty Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Rafferty Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-167,564
Closed -$685K – 1199
2024
Q2 		$685K Sell
167,564
-130,444
-44% -$1.46M ﹤0.01% 885
2024
Q1 		$4.7M Sell
298,008
-62,117
-17% -$854K 0.02% 483
2023
Q4 		$5.46M Buy
360,125
+159,439
+79% +$2.33M 0.02% 429
2023
Q3 		$4.03M Sell
200,686
-50,271
-20% -$1.28M 0.02% 444
2023
Q2 		$7.08M Buy
250,957
+42,039
+20% +$1.01M 0.04% 336
2023
Q1 		$3.59M Sell
208,918
-20,430
-9% -$414K 0.02% 467
2022
Q4 		$4.62M Buy
229,348
+45,563
+25% +$980K 0.04% 385
2022
Q3 		$3.98M Buy
183,785
+58,538
+47% +$1.6M 0.04% 371
2022
Q2 		$3.52M Buy
125,247
+4,077
+3% +$108K 0.03% 355
2022
Q1 		$5.59M Buy
121,170
+55,971
+86% +$3.02M 0.03% 359
2021
Q4 		$5.48M Buy
65,199
+27,611
+73% +$2.14M 0.03% 355
2021
Q3 		$2.5M Sell
37,588
-8,860
-19% -$511K 0.02% 564
2021
Q2 		$2.47M Sell
46,448
-19,078
-29% -$1.02M 0.02% 609
2021
Q1 		$2.84M Buy
65,526
+59,373
+965% +$2.56M 0.02% 525
2020
Q4 		$320K Buy
+6,153
New +$278K ﹤0.01% 794

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Rafferty Asset Management's ZNTL Position: Q3 2024 in Review

Rafferty Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 167,564 shares — an estimated $685K sold.

Rafferty Asset Management first reported a position in ZNTL in Q4 2020 and held it in 15 quarters. The position peaked at $7.08M in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Rafferty Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 167,564 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $685K.
  • Rafferty Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Rafferty Asset Management's Zentalis Pharmaceuticals position peaked at $7.08M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.